跳至主要内容
临床试验/ISRCTN39374171
ISRCTN39374171已完成4 期

A phase IV acceptability and feasibility trial of the effects of medication on memory in idiopathic nondementing Parkinson's disease

niversity Hospital of North Staffordshire (UK)0 个研究点目标入组 22 人开始时间: 2013年6月12日最近更新:

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
22

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Demographic characteristics:
  • 1. Males and females
  • 2. Aged between 50-80 years
  • Medical condition:
  • 1. Idiopathic, sporadic Parkinson?s disease, diagnosed by as determined by the UK Parkinson?s Disease Society Brain Bank Clinical Diagnostic Criteria (1992) Parkinson?s disease stages, mild: 1, 2, 2.5; or moderate: 3 and 4, as determined by the modified Hoehn-Yahr (HY) disease severity rating scale
  • 2. Capacity to provide fully informed signed consent
  • Indicated treatments:
  • 1. Currently medicated with slow release preparations of either pramipexole ER or ropinirole XL
  • 2. Adjuvant therapy with ldopa and/or a monoamine oxidase B inhibitor (such as rasagiline/AZILECT or selegiline/ ELDEPRYL, ZELAPAR)
  • Target Gender: Male & Female; Upper Age Limit 80 years ; Lower Age Limit 50 years

排除标准

  • Demographic characteristics:
  • 1. Patient-participants younger than 50 and older than 80 years of age
  • 2. English is a second language
  • Medical, psychiatric, developmental conditions:
  • 1. Cognitive impairment as assessed with the Mini-Mental State Examination scoring of 25 or less
  • 2. Familial Parkinson'?s disease
  • 3. Severe Parkinson?'s disease, indicated by a score of 5 on the Hoehn and Yahr disease severity rating scale
  • 4. Unable to provide informed consent due to cognitive decline
  • 5. Comorbid for another neurological illness (other than Parkinson?s disease)
  • 6. History of learning difficulty including dyslexia
  • 7. Physical inability to attend or comply with treatment scheduling, such as upper limb amputations, Crippling degenerative arthritis
  • 8. Current or planned participation in another clinical trial or study
  • 9. Active malignancy
  • 10. Pre-planned or elective surgeries during the period of involvement in the trial
  • 11. Prior or current history (within the previous 5 years) of significant and/or uncontrolled drug abuse or alcoholism
  • 12. Major psychotic phenomenology including hallucinations or lack of awareness of dyskinesias
  • 13. Hypotension: severe dizziness or fainting on standing
  • 14. Impulse control disorders or compulsive behaviours
  • 15. Incapacitating dyskinesias on a stable dose of ldopa
  • 16. Hepatic impairment
  • 17. Severe renal impairment (creatinine clearance < 50 ml/min)
  • 18. eGFR of less than 50 ml/min/1.73m(squared)
  • 19. Women of child bearing potential unless they are using a recognized, effective form of contraception or they are not sexually active and have no intention of becoming sexually active during the duration of their involvement in the trial
  • 20. Contraindicated treatments
  • 21. Patient-participants taking any of the following drugs:
  • 21.1. COMT inhibitors (entacapone/COMTAN or tocapone/TASMAR)
  • 21.2. Apomorphine
  • 21.3. Amantadine (population pharmacokinetic analyses suggest that amantadine may slightly decrease the oral clearance of pramipexole)
  • 21.4. Anticholinergics
  • 21.5. Dopamine antagonists (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, ciprofloxacin
  • 21.6. Immediate-release preparations of either pramipexole or ropinirole
  • 22. Patient- participants treated with deep brain stimulation

研究者

发起方
niversity Hospital of North Staffordshire (UK)

相似试验